Gel Documentation Systems Segmentation
End user (Pharmaceutical & Biotech Companies, Academic & Research Institutes, Contract Research Organizations (CROs))
In terms of end users, the pharmaceutical & biotech companies segment is expected to dominate the gel documentation systems market with a share of 35.5% over the assessed period. The efficacy of GDS in enhancing quality and scalability in drug discovery and biologics development is amplifying this segment's contribution to maximum revenue generation. This can be testified by the collective data from the Pharmaceutical Research and Manufacturers of America, the European Federation of Pharmaceutical Industries and Associations, and the Biotechnology Innovation Organization. It calculated the total biopharmaceutical R&D investments from across the U.S., Europe, and Asia Pacific to be USD 256.3 billion in 2023.
Application (Protein Analysis, Nucleic Acid Analysis, Others)
The nucleic acid analysis segment is poised to capture a significant share of 28.6% in the gel documentation systems market by 2037. Its substantial augmentation is majorly pledged to its pivotal role in conducting molecular biology research. Particularly, in DNA/RNA separation, quantification, and quality control, the contribution of this analysis method is highly prioritized by biotech developers. Thus, the growing investments and involvement in genomics research, PCR product analysis, and CRISPR validation from academia, healthcare authorities, and pharmaceutical companies are also fueling a stable capital influx in this segment. Moreover, the rapid modernization of life sciences research and diagnosis is positioning this category at the forefront of greater revenue generation in this merchandise.
Our in-depth analysis of the global gel documentation systems market includes the following segments:
|
Application |
|
|
End user |
|
|
Product Type |
|
